profit from every $100 of sales.
$0$100
Xenon Pharmaceuticals
$40.48-1.26% today
+1.1% in 1 year
1-year low $33.491-year high $70.96
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Xenon Pharmaceuticals sold, what it kept, and what it did with the cash.
Sales went from $9.43 million in 2022 to $7.50 million in 2025, with -$346 million of profit last year.
SalesProfit
Xenon Pharmaceuticals vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Xenon Pharmaceuticals | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Xenon Pharmaceuticals's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 9 | 0 | 0 | 8 | |
| – | – | – | – | |
| -129 | -214 | -279 | -373 | |
| -128 | -212 | -277 | -371 | |
| -125 | -182 | -234 | -346 | |
| -2.06 | -2.73 | -3.01 | -4.36 | |
| – | – | – | – | |
| -1,368.9% | – | – | -4,974.3% | |
| -1,328.9% | – | – | -4,612.1% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 754 | 965 | 798 | 633 |
| Cash | 57 | 149 | 143 | 199 |
| Total debt | 10 | 11 | 9 | 8 |
| Total liabilities | 33 | 37 | 43 | 51 |
| 721 | 928 | 755 | 582 | |
| 61 | 67 | 78 | 79 | |
| -13.9% | -18.0% | -28.9% | -50.0% | |
| -17.4% | -19.7% | -31.0% | -59.5% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -101 | -151 | -181 | -279 | |
| 3 | 6 | 3 | 1 | |
| -104 | -157 | -184 | -280 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 20 | 32 | 51 | 54 |
Valuation
- –
- –
- –
- 6.3×
- 530.5×
- –
- –
- -7.0%
- -8.7%
- 0.0%
Profitability
- 0.0%
- -4,974.3%
- -4,612.1%
- 0.0%
- -51.2%
- -28.4%
- -49.2%
- -27.6%
- -30.6%
- –
Growth
- −7.4%
- –
- −51.7%
- –
- +9.4%
Financial health
- -0.5×
- 0.01
- 0.5%
- –
- 13.42
- 27.79
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 7%of 946
Bottom 8%of 868
Bottom 15%of 986
What analysts expect
- Average price target
- $87.88
- Range
- $60.00 – $100.00
- 10 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | -1.17 | -1.17 | +0.0% |
| Feb 26, 2026 | -1.31 | -1.20 | −9.2% |
| Nov 3, 2025 | -1.15 | -1.16 | +0.9% |
| Aug 11, 2025 | -1.07 | -1.03 | −3.9% |
| May 12, 2025 | -0.83 | -0.94 | +11.7% |
| Feb 27, 2025 | -0.84 | -0.89 | +5.6% |
| Nov 12, 2024 | -0.81 | -0.82 | +0.7% |
| Aug 8, 2024 | -0.75 | -0.72 | −4.2% |
News
Xenon downgraded at Deutsche Bank after pause in depression trialsSeeking Alpha · Sep 18, 2026The newest story we have is from Sep 18, 2026.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
22No pass
Benjamin Graham
40No pass
Philip Fisher
29No pass
Peter Lynch
40No pass
Joel Greenblatt
0No pass
Charlie Munger
28No pass
Terry Smith
25No pass
Questions about Xenon Pharmaceuticals
Is Xenon Pharmaceuticals a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Xenon Pharmaceuticals AI analysis
What does Xenon Pharmaceuticals do?
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. It is in Biotechnology, based in Burnaby, BC, Canada, with 358 employees.
Does Xenon Pharmaceuticals pay a dividend?
No. Xenon Pharmaceuticals does not pay a dividend at the moment.
Is Xenon Pharmaceuticals stock halal?
Yes. Xenon Pharmaceuticals passes our halal screen: its business is permitted and its debt is 0.2% of its market value, under the 30% limit. How we check
How has Xenon Pharmaceuticals stock done over the past year?
Up 1.1% over the past twelve months, to $40.48. It traded between $33.49 and $70.96 and is 43.0% below its high.
Who are Xenon Pharmaceuticals's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Xenon Pharmaceuticals's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.